805 related articles for article (PubMed ID: 32730798)
1. Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase.
Pivonello R; Fleseriu M; Newell-Price J; Bertagna X; Findling J; Shimatsu A; Gu F; Auchus R; Leelawattana R; Lee EJ; Kim JH; Lacroix A; Laplanche A; O'Connell P; Tauchmanova L; Pedroncelli AM; Biller BMK;
Lancet Diabetes Endocrinol; 2020 Sep; 8(9):748-761. PubMed ID: 32730798
[TBL] [Abstract][Full Text] [Related]
2. Osilodrostat, a potent oral 11β-hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing's disease.
Fleseriu M; Pivonello R; Young J; Hamrahian AH; Molitch ME; Shimizu C; Tanaka T; Shimatsu A; White T; Hilliard A; Tian C; Sauter N; Biller BM; Bertagna X
Pituitary; 2016 Apr; 19(2):138-48. PubMed ID: 26542280
[TBL] [Abstract][Full Text] [Related]
3. A multicenter, phase 2 study to evaluate the efficacy and safety of osilodrostat, a new 11β-hydroxylase inhibitor, in Japanese patients with endogenous Cushing's syndrome other than Cushing's disease.
Tanaka T; Satoh F; Ujihara M; Midorikawa S; Kaneko T; Takeda T; Suzuki A; Sato M; Shimatsu A
Endocr J; 2020 Aug; 67(8):841-852. PubMed ID: 32378529
[TBL] [Abstract][Full Text] [Related]
4. Long-term efficacy and safety of osilodrostat in patients with Cushing's disease: results from the LINC 4 study extension.
Gadelha M; Snyder PJ; Witek P; Bex M; Belaya Z; Turcu AF; Feelders RA; Heaney AP; Paul M; Pedroncelli AM; Auchus RJ
Front Endocrinol (Lausanne); 2023; 14():1236465. PubMed ID: 37680892
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of levoketoconazole in the treatment of endogenous Cushing's syndrome (SONICS): a phase 3, multicentre, open-label, single-arm trial.
Fleseriu M; Pivonello R; Elenkova A; Salvatori R; Auchus RJ; Feelders RA; Geer EB; Greenman Y; Witek P; Cohen F; Biller BMK
Lancet Diabetes Endocrinol; 2019 Nov; 7(11):855-865. PubMed ID: 31542384
[TBL] [Abstract][Full Text] [Related]
6. Randomized Trial of Osilodrostat for the Treatment of Cushing Disease.
Gadelha M; Bex M; Feelders RA; Heaney AP; Auchus RJ; Gilis-Januszewska A; Witek P; Belaya Z; Yu Y; Liao Z; Ku CHC; Carvalho D; Roughton M; Wojna J; Pedroncelli AM; Snyder PJ
J Clin Endocrinol Metab; 2022 Jun; 107(7):e2882-e2895. PubMed ID: 35325149
[TBL] [Abstract][Full Text] [Related]
7. Long-term outcomes of osilodrostat in Cushing's disease: LINC 3 study extension.
Fleseriu M; Newell-Price J; Pivonello R; Shimatsu A; Auchus RJ; Scaroni C; Belaya Z; Feelders RA; Vila G; Houde G; Walia R; Izquierdo M; Roughton M; Pedroncelli AM; Biller BMK
Eur J Endocrinol; 2022 Oct; 187(4):531-541. PubMed ID: 35980235
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of once-monthly pasireotide in Cushing's disease: a 12 month clinical trial.
Lacroix A; Gu F; Gallardo W; Pivonello R; Yu Y; Witek P; Boscaro M; Salvatori R; Yamada M; Tauchmanova L; Roughton M; Ravichandran S; Petersenn S; Biller BMK; Newell-Price J;
Lancet Diabetes Endocrinol; 2018 Jan; 6(1):17-26. PubMed ID: 29032078
[TBL] [Abstract][Full Text] [Related]
9. LCI699, a potent 11β-hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushing's disease: results from a multicenter, proof-of-concept study.
Bertagna X; Pivonello R; Fleseriu M; Zhang Y; Robinson P; Taylor A; Watson CE; Maldonado M; Hamrahian AH; Boscaro M; Biller BM
J Clin Endocrinol Metab; 2014 Apr; 99(4):1375-83. PubMed ID: 24423285
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of lower-sodium oxybate in adults with idiopathic hypersomnia: a phase 3, placebo-controlled, double-blind, randomised withdrawal study.
Dauvilliers Y; Arnulf I; Foldvary-Schaefer N; Morse AM; Šonka K; Thorpy MJ; Mignot E; Chandler P; Parvataneni R; Black J; Sterkel A; Chen D; Skobieranda F; Bogan RK
Lancet Neurol; 2022 Jan; 21(1):53-65. PubMed ID: 34942138
[TBL] [Abstract][Full Text] [Related]
11. Osilodrostat: A Novel Steroidogenesis Inhibitor to Treat Cushing's Disease.
Dougherty JA; Desai DS; Herrera JB
Ann Pharmacother; 2021 Aug; 55(8):1050-1060. PubMed ID: 33143437
[TBL] [Abstract][Full Text] [Related]
12. Long-term efficacy and safety of osilodrostat in Cushing's disease: final results from a Phase II study with an optional extension phase (LINC 2).
Fleseriu M; Biller BMK; Bertherat J; Young J; Hatipoglu B; Arnaldi G; O'Connell P; Izquierdo M; Pedroncelli AM; Pivonello R
Pituitary; 2022 Dec; 25(6):959-970. PubMed ID: 36219274
[TBL] [Abstract][Full Text] [Related]
13. Clinical Utility of Osilodrostat in Cushing's Disease: Review of Currently Available Literature.
Perosevic M; Tritos NA
Drug Des Devel Ther; 2023; 17():1303-1312. PubMed ID: 37143705
[TBL] [Abstract][Full Text] [Related]
14. Pasireotide can induce sustained decreases in urinary cortisol and provide clinical benefit in patients with Cushing's disease: results from an open-ended, open-label extension trial.
Schopohl J; Gu F; Rubens R; Van Gaal L; Bertherat J; Ligueros-Saylan M; Trovato A; Hughes G; Salgado LR; Boscaro M; Pivonello R;
Pituitary; 2015 Oct; 18(5):604-12. PubMed ID: 25537481
[TBL] [Abstract][Full Text] [Related]
15. Osilodrostat for the treatment of Cushing's disease.
Rasool S; Skinner BW
Expert Opin Pharmacother; 2021 Jun; 22(9):1099-1106. PubMed ID: 33703978
[TBL] [Abstract][Full Text] [Related]
16. Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial.
Ramanan AV; Quartier P; Okamoto N; Foeldvari I; Spindler A; Fingerhutová Š; Antón J; Wang Z; Meszaros G; Araújo J; Liao R; Keller S; Brunner HI; Ruperto N; ;
Lancet; 2023 Aug; 402(10401):555-570. PubMed ID: 37423231
[TBL] [Abstract][Full Text] [Related]
17. Corticotroph tumor progression during long-term therapy with osilodrostat in a patient with persistent Cushing's disease.
Fontaine-Sylvestre C; Létourneau-Guillon L; Moumdjian RA; Berthelet F; Lacroix A
Pituitary; 2021 Apr; 24(2):207-215. PubMed ID: 33074401
[TBL] [Abstract][Full Text] [Related]
18. Treatment of paediatric narcolepsy with sodium oxybate: a double-blind, placebo-controlled, randomised-withdrawal multicentre study and open-label investigation.
Plazzi G; Ruoff C; Lecendreux M; Dauvilliers Y; Rosen CL; Black J; Parvataneni R; Guinta D; Wang YG; Mignot E
Lancet Child Adolesc Health; 2018 Jul; 2(7):483-494. PubMed ID: 30169321
[TBL] [Abstract][Full Text] [Related]
19. Tasimelteon for non-24-hour sleep-wake disorder in totally blind people (SET and RESET): two multicentre, randomised, double-masked, placebo-controlled phase 3 trials.
Lockley SW; Dressman MA; Licamele L; Xiao C; Fisher DM; Flynn-Evans EE; Hull JT; Torres R; Lavedan C; Polymeropoulos MH
Lancet; 2015 Oct; 386(10005):1754-64. PubMed ID: 26466871
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study.
Reuter U; Goadsby PJ; Lanteri-Minet M; Wen S; Hours-Zesiger P; Ferrari MD; Klatt J
Lancet; 2018 Nov; 392(10161):2280-2287. PubMed ID: 30360965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]